Concepedia

Author

Johan Van Hoof

Janssen (Netherlands)

Also Known As

C Pearson, J Van Hoof, J van Hoof, J. Van Hoof, J. van Hoof, Johan Van Hoof, Johan van Hoof, Krammer, Florian, Strasbaugh, Amanda, Wesley Van Ever

48

Publications

6.8K

Citations

20

H-Index

55

Concepts

All Affiliations

Janssen (Netherlands)Janssen (Belgium)University of AntwerpBeth Israel Deaconess Medical CenterJanssen (United States)
JV

About

Johan Van Hoof is an author at Janssen (Netherlands) specializing in medicine, vaccination, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

11

1.3K

2

Biology

2

2

29

3

Natural Sciences

1

1

12

4

Public Health

1

1

12

5

Biochemistry

1

1

12

Johan Van Hoof

×

24

Publications

6.4K

Citations

18

H-Index

YearCitations

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Jerald Sadoff, Glenda Gray, An Vandebosch,

New England Journal of Medicine

2021

2.5K

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev,

New England Journal of Medicine

2021

1.2K

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Noe B. Mercado, Roland Zahn, Frank Wegmann,

Nature

2020

889

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Galit Alter, Jingyou Yu, Jinyan Liu,

Nature

2021

342

Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines

Iain Milligan, Malick M. Gibani, Richard P. Sewell,

JAMA

2016

321

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

Kathryn E. Stephenson, Mathieu Le Gars, Jerald Sadoff,

JAMA

2021

313

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Jerald Sadoff, Glenda Gray, An Vandebosch,

New England Journal of Medicine

2022

246

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial

Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev,

2020

141

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Karin Hardt, An Vandebosch, Jerald Sadoff,

The Lancet Infectious Diseases

2022

84

A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti–Zika Virus Vaccine

Nadine C. Salisch, Kathryn E. Stephenson, Kristi L. Williams,

Annals of Internal Medicine

2021

76

Page 1